Ownes & Minor (OMI) Misses Q1 EPS by 4c, Miss on Revenues
Get Alerts OMI Hot Sheet
Revenue Growth %: +4.4%
Financial Fact:
Net income: 29.83M
Today's EPS Names:
SEIC, OSBC, USAP, More
Join SI Premium – FREE
Ownes & Minor (NYSE: OMI) reported Q1 EPS of $0.43, $0.04 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.4 billion.
- O&M completes acquisition of Halyard Health’s Surgical & Infection Prevention (S&IP) business
- Consolidated quarterly revenues were $2.37 billion vs. $2.33 billion a year ago
- EPS for the quarter was $0.13, while non-GAAP adjusted EPS was $0.43
“We are pleased to have completed the acquisition of Halyard Health’s S&IP business, which represents a meaningful step in the evolution of our business. Together, the Halyard S&IP business and Byram Healthcare serve to strengthen and diversify our business model,” said P. Cody Phipps, chairman, president & chief executive officer of Owens & Minor. “Our quarterly results improved sequentially, consistent with our expectations, as we continued to transform our business. By combining the Halyard S&IP business with our existing products group, our Global Products strategic business unit has an enhanced presence in the medical products sector with approximately $1.5 billion in annualized revenues. This transaction gives Owens & Minor a global platform for growth with a strong product portfolio and exceptional teammates.”
For earnings history and earnings-related data on Ownes & Minor (OMI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
- United Microelectronics (UMC) Reports In-Line Q1 EPS, provides outlook
- Baker Hughes Company (BKR) Tops Q1 EPS by 4c, Beats on Revenue
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!